AI framework designs mRNA vaccines that survive months without refrigeration

Messenger RNA vaccines transformed the world’s response to the COVID-19 pandemic, but their Achilles heel has always been temperature. The lipid nanoparticles that deliver mRNA into cells are exquisitely fragile, and the leading formulations must be kept at deep-freeze temperatures from the moment they are manufactured until the instant they are injected. For wealthy countries with robust logistics networks, that constraint is expensive; for much of the world, it is prohibitive. Now a research team reporting in Nature Biotechnology has unveiled an artificial intelligence framework, called AGENT, that can rapidly engineer thermostable, solid-state mRNA vaccines capable of retaining full biological activity after two months of storage at 37 degrees Celsius, roughly the temperature of a hot summer day.

The work, summarized in a Research Briefing by Nature Biotechnology, combines two ingredients that have rarely been brought together so systematically: high-throughput experimentation and Bayesian optimization. Bayesian optimization is a machine learning strategy designed for exactly the kind of problem the vaccine engineers faced, in which each experiment is costly, the search space of possible formulations is vast, and the relationship between the ingredients and the outcome is complex and poorly understood. Rather than testing every conceivable combination of stabilizing sugars, buffering agents, drying protocols and nanoparticle compositions, the algorithm builds a probabilistic model of the formulation landscape from the data gathered so far, then selects the next experiment where the expected gain in information or performance is highest.

This data-efficient approach matters because traditional formulation development is notoriously slow. A medicinal chemist or vaccine formulator might adjust one variable at a time, run stability assays that take days or weeks to complete, and iterate over months or years. By contrast, AGENT closes the loop: robotic high-throughput platforms prepare large batches of candidate formulations, automated assays measure their stability and bioactivity, and the Bayesian optimizer digests each round of results to propose an improved set of conditions for the next. The framework effectively takes the human out of the loop for the routine decision-making, reserving human judgment for defining the objectives and validating the final candidates.

The target of the optimization was a solid-state mRNA vaccine, meaning that the mRNA-lipid nanoparticles are dried into a stable matrix rather than suspended in liquid. Drying is a well-known route to thermal stability for biological drugs, as the absence of water dramatically slows the hydrolysis and other degradation reactions that destroy RNA. But the drying process itself is stressful: ice crystals, osmotic shocks and the removal of the hydration shell can shear nanoparticles, aggregate them, or otherwise wreck the delicate structure that allows them to fuse with cell membranes and release their payload. The art lies in choosing protective excipients, often sugars such as trehalose or sucrose, and processing conditions that let the nanoparticles pass through drying and reconstitution unscathed.

The results reported by Tian and colleagues are striking on several fronts. The optimized solid-state formulations retained full bioactivity after two months of storage at 37 degrees Celsius, a condition far beyond anything current liquid mRNA vaccines can tolerate. In immunization studies, these stored vaccines elicited immune responses that were non-inferior to those generated by fresh, never-stressed formulations, which is the critical regulatory benchmark: a thermostable vaccine is only useful if it works as well as the product it replaces. Stability at room temperature and above would allow vaccines to be shipped and stored without the elaborate cold chain of ultra-low-temperature freezers, dry ice and temperature loggers that dominates current distribution.

The team went beyond vials and syringes. The thermostable mRNA formulations were incorporated into microneedle patches, small arrays of dissolving needles that painlessly deliver vaccine into the skin. Microneedle delivery has been pursued for years as a needle-free, potentially self-administered vaccination platform, and earlier work from some of the same community demonstrated a microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. The new study extends that vision by showing that the AI-optimized, cold-chain-free formulations could be delivered via microneedle patches in rodents and nonhuman primates, providing proof of concept in animals that are far closer to humans than cell cultures or mice alone.

The combination of thermostability and patch delivery points toward a fundamentally different model of vaccine distribution. A vaccine that survives months at 37 degrees Celsius and can be applied as a patch requires no freezer, no trained phlebotomist, no reconstitution step and minimal medical waste. In resource-constrained settings, where the cited literature on vaccine accessibility emphasizes that storage and distribution bottlenecks cost lives, such a product could reach communities that conventional campaigns struggle to serve. It would also simplify pandemic preparedness, since stockpiles would not depend on a continuous chain of refrigeration stretching from factory to clinic.

From a technical standpoint, the study is a showcase of how modern machine learning changes the economics of formulation science. Bayesian optimization is particularly suited to problems with expensive evaluations because it balances exploration and exploitation: it probes regions of the design space where the model is uncertain, while also refining candidates that already look promising. The framework’s data efficiency means that the number of physical experiments needed to reach an optimized formulation can be a fraction of what a grid search or one-variable-at-a-time approach would demand. Each experiment feeds back into a surrogate model, typically a Gaussian process or similar probabilistic regressor, which quantifies not just the predicted performance of untested formulations but the confidence in those predictions.

The subjects attached to the paper, spanning biomaterials for vaccines, biomedical engineering, DNA and RNA science, and nanoparticles, reflect the interdisciplinary nature of the achievement. The mRNA-lipid nanoparticle platform sits at the intersection of nucleic acid chemistry, colloid science, polymer physics and immunology, and no single discipline could have solved the stability problem alone. What AGENT contributes is a unifying optimization layer that treats the entire formulation-and-processing pipeline as a single search problem, allowing trade-offs to be navigated automatically. A choice of excipient that improves drying stability but slows release, for example, can be weighed against alternatives in a principled way rather than by intuition.

Caveats remain, as they always do at this stage of translation. The immunogenicity data are from rodents and nonhuman primates, and human clinical trials will be needed to confirm that the optimized solid-state vaccines match the performance of approved liquid products in people. Two months of stability at 37 degrees Celsius is a dramatic improvement, but regulators will want to see longer-term data across a range of temperatures and humidities, along with manufacturing scale-up studies. Nonetheless, the demonstration that an AI-driven, data-efficient framework can compress years of formulation development into a rapid, systematic campaign is itself a significant result. If the approach generalizes to other mRNA drugs and vaccine targets, the cold chain that has long constrained global health delivery may finally begin to loosen.

Subject of Research: AI-guided Bayesian optimization for the development of thermostable, solid-state mRNA-lipid nanoparticle vaccines

Article Title: AI-guided optimization for thermostable mRNA vaccines

Article References: AI-guided optimization for thermostable mRNA vaccines. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03330-x (Author names are not included in the publisher’s citation export.)

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03330-x

Keywords: mRNA vaccines, artificial intelligence, Bayesian optimization, lipid nanoparticles, thermostability, cold chain, microneedle patches, high-throughput experimentation, vaccine formulation, global health, biotechnology, immunization